Baker Hughes: M&A Activity

The leadership read

The EC's conditional approval commits Baker Hughes to a divestment process it did not face when the deal was announced, meaning the combined entity's LNG asset footprint is now being shaped in part by Brussels, not solely by management. That is a materially different integration problem: the company must simultaneously execute a $13.6 billion combination and carve out regulated assets in one of the most scrutinized energy infrastructure categories in Europe. Divestment conditions at this scale require dedicated transaction and regulatory operations running in parallel to integration planning, not sequentially. This is one of 12 M&A signals we have tracked across sectors in the last 90 days, though the Baker Hughes–Chart transaction is the only one in energy infrastructure at this scale with a conditional regulatory clearance attached. The broader batch. GSK's $10.6 billion Nuvalent close, Lionsgate's reported sale conversations, reflects sustained large-cap deal activity, but few carry the added complexity of mandated asset separation under a supranational regulator. That specificity matters: conditional EC approvals in critical-infrastructure categories create a distinct operational track that straightforward acquisitions do not. Companies navigating this kind of regulatory-conditional close face concentrated demand for leadership at the intersection of regulatory affairs, carve-out transaction management, and post-merger integration, particularly where the divested assets carry customer contracts, operating licenses, or supply-chain dependencies that cannot be cleanly severed. The market is moving toward operators who can manage those seams without disrupting the core combination thesis.